BLA 761358 · Celltrion
Zymfentra
Infliximab-Dyyb · Injection
Last checked: Nov 20, 2026Latest source record: Feb 22, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Oct 20, 2023
Approved uses
1
Original approval plus efficacy supplements
Registered trials
379
125 Phase 3, 45 recruiting
FAERS reports
3,446
2,649 serious, 93 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SERIOUS INFECTIONS and MALIGNANCY See full prescribing information for complete boxed warning Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as hitoplasmosis) and infections due to ohter opportunistic pathogens. (5.1) Discontinue ZYMFENTRA if a patient develops a serious infection or sepsis. (5.1) Perform test for latent TB; if positive, start treatment for TB prior to starting ZYMFENTRA. Monitor all patients for active TB during treatment, even if initial latent TB test is negative. (5.1) Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor (TNF) blockers, including infliximab products. (5.2) Postmarketing cases of fatal hepatosplenic T-cell lymphoma (HSTCL) have been reported in patients...
What it is approved for
From the label in effect Aug 18, 2026.
ZYMFENTRA is a tumor necrosis factor (TNF) blocker indicated in adults for maintenance treatment of: moderately to severely active ulcerative colitis following treatment with an infliximab product administered intravenously. ( 1 ) moderately to severely active Crohn’s disease following with an infliximab products administered intraneously. ( 1 ) ZYMFENTRA is indicated in adults for maintenance treatment of: moderately to severely active ulcerative colitis following treatment with an infliximab product administered intravenously. moderately to severely active Crohn's disease following treatment with an infliximab product administered intravetnously.
Mechanism: Infliximab-dyyb neutralize the biological activity of TNFα by binding with high affinity to the soluble and transmembrane forms of TNFα and inhibit binding of TNFα with its receptors. Infliximab-dyyb has shown biological activities, such as TNFα neutralization activity and TNFα binding affinities, complement 1q (C1q) binding affinity and crystallizable fragment (Fc) receptor binding affinities in a wide variety of in vitro bioasays. The relationship of these biological response markers to the mechanism(s) by which infliximab-dyyb exerts its clinical effects is unknown.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 20, 2023 Original approval · Type 3 - New Dosage Form LetterLabelMedication Guide
1 products under this application
- ZYMFENTRA · INFLIXIMAB-DYYB 120MG/ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Infliximab" as an intervention, any sponsor and status, largest first.
- Treatments for COVID-19: Canadian Arm of the SOLIDARITY TrialPivotal-lookingStatus unknown
Sunnybrook Health Sciences CentreAcademic, hospital or other
NCT04330690 · 2,900 participants (planned) · Start Mar 18, 2020 · Primary completion Mar 10, 2024
Drug: Artesunate; Imatinib and 3 more · For: COVID-19
Sites: Calgary, Canada; Edmonton, Canada; Kamloops, Canada · 53 sites in all
- Immune Modulators for Treating COVID-19Pivotal-lookingCompleted
Daniel BenjaminAcademic, hospital or other
NCT04593940 · 1,971 participants · Start Oct 15, 2020 · Primary completion Jan 30, 2022
Drug: Infliximab; Abatacept and 2 more · For: Covid19
Sites: Phoenix, Arizona; Little Rock, Arkansas; La Jolla, California · 91 sites in all
- Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF TherapyPivotal-lookingCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT00124982 · 1,286 participants · Start Apr 2005 · Primary completion Aug 2009
Drug: Abatacept; Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD) and 1 more · For: Rheumatoid Arthritis
Sites: Birmingham, Alabama; Huntsville, Alabama; Paradise Valley, Arizona · 148 sites in all
- Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's DiseaseActive, not recruiting
Connecticut Children's Medical CenterAcademic, hospital or other
NCT05781152 · 1,270 participants · Start Jun 10, 2023 · Primary completion Jul 1, 2028
Drug: Anti-TNF therapy · For: Crohn Disease
Sites: Phoenix, Arizona; Los Angeles, California; San Diego, California · 26 sites in all
- Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological ImmunotherapieRecruiting
IsalaAcademic, hospital or other
NCT06031233 · 1,082 participants (planned) · Start Sep 1, 2023 · Primary completion Jul 2028
Drug: Nivolumab; Pembrolizumab and 9 more · For: Oncology; Infusion Reaction
Sites: Zwolle, Netherlands
- Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE)Pivotal-lookingCompleted
AbbottIndustry
NCT00338650 · 1,000 participants · Start Jun 2006
Drug: adalimumab · For: Crohn's Disease
Sites: Birmingham, Alabama; Jonesboro, Arkansas; Little Rock, Arkansas · 97 sites in all
- HLADQA1*05 Genotype and the Efficacy of Treatment With Infliximab in Chinese Population Crohn's DiseasePivotal-lookingStatus unknown
Sixth Affiliated Hospital, Sun Yat-sen UniversityAcademic, hospital or other
NCT05813860 · 976 participants (planned) · Start Apr 30, 2023 · Primary completion May 31, 2026
Drug: Azathioprine; Infliximab · For: Crohn Disease; Infliximab
- The Effects of Infliximab Versus Methotrexate in the Treatment of Moderate to Severe Psoriasis (Study P04271AM2)(COMPLETED)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00251641 · 868 participants · Start Sep 1, 2005 · Primary completion Jun 1, 2008
Drug: infliximab; methotrexate · For: Psoriasis
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- inappropriate schedule of product administration991
- off label use908
- intentional dose omission840
- product dose omission issue448
- overdose320
- suspected off label use311
- weight decreased306
- weight increased306
- therapy interrupted294
- arthralgia288
- fatigue286
- condition aggravated272
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2017 | 2 |
| 2018 | 12 |
| 2019 | 7 |
| 2020 | 9 |
| 2021 | 25 |
| 2022 | 59 |
| 2023 | 153 |
| 2024 | 382 |
| 2025 | 882 |
| 2026 | 1,915 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Zymfentra (Infliximab-Dyyb)
2024 spending
$222K
Beneficiaries
15
39 claims
Per beneficiary
$14,802
$2,741.20 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $222,037 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative efficacy of biologics and oral agents in palmoplantar psoriasis and palmoplantar pustulosis: A systematic review and network meta-analysis of randomized clinical trials.
Spencer RK, Jin JQ, Elhage KG, et al. · J Am Acad Dermatol 2023 · Letter, Network Meta-Analysis
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.
Hanauer SB, Feagan BG, Lichtenstein GR, et al. · Lancet 2002 · Clinical Trial, Multicenter Study
- Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.
Singh S, Murad MH, Fumery M, et al. · Lancet Gastroenterol Hepatol 2021 · Comparative Study, Research Support, N.I.H., Extramural
- Infliximab versus Cyclophosphamide for Severe Behçet's Syndrome.
Saadoun D, Maalouf G, Vieira M, et al. · NEJM Evid 2024 · Clinical Trial, Phase II, Comparative Study
- Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn's disease: systematic review and network meta-analysis.
Barberio B, Gracie DJ, Black CJ, et al. · Gut 2023 · Systematic Review, Network Meta-Analysis
- Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: a randomised controlled, open-label, multicentre trial.
Ponsioen CY, de Groof EJ, Eshuis EJ, et al. · Lancet Gastroenterol Hepatol 2017 · Comparative Study, Multicenter Study
Sponsor: Celltrion
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.